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Background: Mycobacterium bovis bacillus Calmette Guérin (BCG) vaccine, which has been inoculated to more than
one billion people world-wide, has significant effect in preventing tuberculous meningitis and miliary tuberculosis
(TB) in neonate and early childhood. However, BCG fails to adequately protect against pulmonary TB and
reactivation of latent infections in adults. To overcome this problem, adequate booster is urgently desired in adult
who received prior BCG vaccination, and appropriate animal models that substitute human cases would be highly
valuable for further experimentation.
Findings: The booster effect of the synthesized CpG oligomer (Oligo-B) on aged mice which had been primarily
vaccinated with BCG at the age of 4-week old. The specific Th1 type reaction, production of interferon-γ, in
response to TB antigens, purified protein derivatives (PPD) and protection against challenge with Mycobacterium
tuberculosis (MTB) H37Rv decreased with increasing age and were not observed in 89-week old mice. In order to
rejuvenate the Th1 type response against PPD and protection activity against MTB infection, Oligo-B, which is
known to augment Th1 responses, was administered as a booster to 81-90-week old mice (late 50’s in human
equivalent) vaccinated with BCG at 4-week old. The boosting with Oligo-B increased the number of CD4+ CD44high
CD62Lhigh, central memory type T cell. Furthermore, the Oligo-B boosting rejuvenated the ability of mice to protect
against infection with MTB H37Rv.
Conclusions: Th1-adjuvant CpG oligo DNA, such as Oligo-B, may be a promising booster when coupled with BCG
priming.
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The protective efficacy of BCG vaccine is variable from
0 to 80% in many field trials and uncertain to pulmon-
ary TB in adult [1]. The several reports showed that the
effectiveness of prime BCG vaccination would last for
around 15–24 years [2,3]. To solve the problem of* Correspondence: ttakii@phar.nagoya-cu.ac.jp
1Department of Molecular Health Sciences, Graduated School of
Pharmaceutical Sciences, Nagoya City University, 3-1, Tanabe, Mizuho-ku,
Nagoya 467-8603, Japan
Full list of author information is available at the end of the article
© 2013 Taniguchi et al.; licensee BioMed Cent
Commons Attribution License (http://creativec
reproduction in any medium, provided the orcurrent BCG vaccine the prime-boost vaccine strategy
against TB was investigated strategy [4,5]. In most of
the trials in mice, however, intervals between priming
and boosting were only 4–8 weeks, which correspond to
2 years in human. Furthermore, the immune response
against MTB reaches its peak within several weeks after
prime vaccination. Thereby, to evaluate the booster in
adult human, it is necessary to investigate the boosting
effect in aged animals primed with BCG. The transition
of immune system with increasing age has been
reported by analyzing the population of T cell subsetsral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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efficacy of BCG vaccination and the shift of memory
type T cell subsets with increasing age are very few. In
this study we investigated the efficacy of prime BCG
vaccine with aging by analyzing memory T cell subset,
immune responses to TB antigens, and also protection
activity against MTB infection in animal model. We also
evaluated the effect of boosting with Oligo-B to the pro-
tective immunity against TB in BCG-primed aged mice.
Materials and methods
1. Bacterial strains and cultures
2. Mice and immunizationThe methods were described in our previous
study [9]. The protocol of animal study was
approved by the Ethics Committee of Nagoya City
University.
3. Whole blood assay
The whole blood was stimulated with purified
protein derivative (PPD) (Japan BCG co., Tokyo,
Japan) for 18 h. Then, the supernatant were
collected and the amount of interferon gamma
(IFN-γ) was measured by enzyme-linked
immunosorbent assay (ELISA), using a BD
OptEIATM ELISA set (BD Bioscience,
San Jose, CA).
4. Flow cytometric analysis of surface markers
Splenocytes from young and middle-aged mice
were washed by FACS buffer and stained with PE
rat anti-mouse CD8a (BD Bioscience, San Jose,
CA) and FITC rat anti-mouse CD4 (BD
Bioscience, San Jose, CA), then analyzed by FACS.
MACSTM(Miltenyi Biotec, Tokyo, Japan) -purified
splenocytes CD4+ and CD8+ T cells were stained
with PE rat anti-mouse CD44 and FITC rat
anti-mouse CD62L (BD Bioscience, San Jose, CA),
then cells were analyzed by FACS.
5. Protection assay against infection with MTB
The precise method was described in our previous
study [9].
6. Splenocytes stimulation
Splenocytes prepared from BCG-immunized with
or without Oligo-B (GGGGGGGGGGGG
AACGTTGGGGGGGGGGGG) (Nihon Gene
Research Laboraroties, Inc., Miyagi, Japan) or
Oligo-B negative (GGGGGGGGGGGG
ACCGGTGGGGGGGGGGGG) (Nihon Gene
Research Laboraroties, Inc., Miyagi, Japan) mice
were incubated in a 24-well plate, at a
concentration of 5 × 105 cells per well. Cells were
stimulated with 10 μg/ml of PPD for 48 h. The
productions of IFN-γ in the supernatants of
splenocytes were determined by the ELISA set.7. Statistical analysis
The methods were described in our previous study
[9].
Results
1. The reduction of interferon-γ production from
antigen-stimulated T cells of mice immunized with
Mycobacterium bovis bacillus Calmette Guérin
(BCG) with aging
The difference of the PPD-induced IFN-γ
production between unvaccinated and vaccinated
mice with BCG at 4-week old was remarkable until
49-week old mice (Figure 1a-1g), however, it was not
significant in 57-week and 83-week old mice
(Figure 1h and 1i). The PPD-induced IFN-γ
production in unvaccinated mice was comparable to
that of BCG vaccinated super aged mice (83-week
old) (Figure 1i). The immune response to ovalbumin
(OVA), non-specific antigen, increased in both
unvaccinated and BCG vaccinated 83-week old mice
(Figure 2b). These results suggest that the immune
responses specific to tuberculosis antigen decreased,
and conversely nonspecific immune responses
increased with aging and were supported previous
studies about immune senescence with aging [6-8].
2. The change of memory type T cell subsets with
aging
We analyzed central type memory T cells (TCM),
CD44hi CD62Lhi, and effector type memory T cells
(TEM), CD44
hi CD62Llo, in both 30-week and
90-week old mice. CD8+ TEM was induced by the
immunization with BCG in 30-week mice (Table 1,
BCG vaccination; 61.7 ± 0.03 vs un-vaccination;
48.2± 7.95), however, the population of TCM did not
change (Table 1, BCG vaccination; 14.7 ± 0.49 vs
un-vaccination; 14.0 ± 3.67 ). Marcela et al. reported
that the immunization with BCG failed to induce
TCM [10]. The population of both TEM and TCM in
CD8+ slightly decreased in BCG-vaccinated 90-week
old mice (Table 1, BCG vaccination; 87.51 ± 6.94 vs
un-vaccination; 95.90 ± 0.82). These data suggest
that the immunization with BCG is not sufficient to
induce long term memory type T cells.
3. Boosting with Oligo-B
Several researches reported that Th1 type responses,
such as production of IFN-γ against PPD, were
reduced with aging and the immunization with BCG
was not sufficient to induce long term memory T
cells [10,11]. We have previously reported that CpG
oligomer (Oligo-B) activate Th1 response [12] and
enhanced the delayed type hypersensitivity against
PPD [13]. Therefore, we investigated the boosting
effect of Oligo-B on the reactivation of immune
Figure 1 The change of IFN-γ production from whole blood cells stimulated with PPD in mice with increasing age. C57BL/6 mice were
subcutaneously vaccinated with BCG (106 CFU) or PBS (unvaccinated). Whole-blood obtained from a) 13-week old, b) 18-week old, c) 24-week
old, d) 28-week old, e) 31-week old, f) 40-week old, g) 49-week old, h) 57-week old, i) 83-week old was stimulated with purified protein derivative
(PPD, solid column) or PBS (open column) and incubated for 24 h. The concentration of interferon-gamma (IFN-γ) from the culture supernatant
was measured by ELISA. Results are shown as mean ± SD from groups of 16 animals. ** p < 0.01,* p < 0.05, N.S.: not significant.
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Oligo-B, but not Oligo-B negative, remarkably
augmented the production of IFN-γ from
splenocytes stimulated with PPD in the BCG
vaccinated mice (Figure 3), and CD4+ memory
type T cells were strongly induced by the boosting
(Table 1, CD4+ CD44hi CD62Lhigh in 90-week old
mice: after boosting; 7.76±3.26 vs before boosting;
2.85 ± 0.67). These results strongly suggest that
the boosting with Oligo-B can effectively
reactivate the memory T cells developed by
primary vaccination.
4. The effect of boosting with Oligo-B on the
protectiveness against MTB in aged mice primarily
vaccinated with BCG
The bacterial numbers of MTB H37Rv challenged
intravenously were reduced in the spleen and lungby BCG vaccination in 30-week old mice
(Figure 4a and 4b). However, at 89-week old, the
reduction of challenged MTB number was not
significant as compared to unvaccinated control
mice (Figure 4c and 4d, open column). After three
times boosting of Oligo-B on the 84-week old
mice vaccinated with or without the prime BCG
vaccination, these mice were challenged with
MTB H37Rv intravenously at 90 weeks old. The
bacterial numbers decreased in the lungs and
spleens from the mice vaccinated prime BCG plus
three times boosting with Oligo-B (Figure 4c and
4d, unvaccinated (open column) vs BCG plus
OligoB (solid column)). These data indicate that
Oligo-B rejuvenates the weakened protective
immunity against MTB infection in BCG-primed
aged mice.
Figure 2 The IFN-γ production from splenocytes stimulated
with OVA in BCG vaccinated young and middle-aged mice.
Splenocytes were prepared from BCG-vaccinated or non-vaccinated
a)13-week old, b) 89-week old mice, and plated in a 24-well plate,
at a concentration of 5 × 105 cells per well. Cells were stimulated
with 100 μg/ml of ovalbumin (OVA, gray column), 10 μg/ml of PPD
(solid column) or PBS (open column) and incubated for 48 h. Then,
supernatants were collected and the concentration of IFN-γ was
measured by ELISA. Results are shown by mean ± SD from groups of
3 mice. ** p < 0.01, * p <0.05, N.S.: not significant.
Table 1 Transition of memory T cells in BCG immunized mice
Oligo-B on memory T cells$
Age Immunization














$Splenocytes were prepared from the aged mice indicated in the table and stained
by a flow cytometer. Precise procedures were described in the Section of Materials
*The age in human equivalent was applied to survival curve of mice.
&Mice were administered transdermally with BCG at 4-week old.
**Effector memory T cell (TEM), CD44
hi CD62Llo; central memory T cell (TCM), CD44
hi
N.D.: not determined.
Figure 3 Oligo-B, but not Oligo-B negative augmented the
prime BCG vaccination. BCG-vaccinated or unvaccinated 30-week
aged mice were subcutaneously injected with 50 μg of booster
(Oligo-B or Oligo-B-negative), every 2 weeks. Splenocytes prepared
from each mouse 2 weeks after 3-times boosting were incubated in
a 24-well plate, at a concentration of 5 × 105 cells per well. Cells
were stimulated with 10 μg/ml of PPD (solid column) or PBS
(open column) and incubated for 48 h. Then, supernatants were
collected and the concentration of IFN-γ was measured by ELISA.
Results are shown as mean ± SD from groups of three mice.
* p < 0.05, N.S.: not significant.
Taniguchi et al. Immunity & Ageing 2013, 10:25 Page 4 of 6
http://www.immunityageing.com/content/10/1/25Discussion
In this study, we first analyzed the age related changes of
immune responses to MTB antigens, in super aged mice
(up to 89-week old) vaccinated with BCG in 4-week old.
The IFN-γ production from whole blood cells from
C57BL/6 mice immunized with BCG at 4-week old in-
creased up to 13-week old and sustained to 49-week old
(Figure 1). These results are consistent with our previouswith aging and retrieval effect of the boosting with
CD4+ CD8+
CD44hi CD62L** CD44hi CD62L**
low (TEM) high (TCM) low (TEM) high (TCM)
72.2 ± 0.82 15.6 ± 0.80 61.7 ± 0.03 14.7 ± 0.49
74.5 ± 1.23 13.8 ± 0.35 48.2 ± 7.95 14.0 ± 3.67
85.75 ± 5.91 2.85 ± 0.67 87.51 ± 6.94 2.07 ± 0.12
93.03 ± 0.56 5.95 ± 0.68 95.90 ± 0.82 3.38 ± 1.94
73.6 ± 1.92 17.3 ± 0.32 53.7 ± 10.3 9.95 ± 0.15
78.1 ± 3.89 14.6 ± 0.88 51.8 ± 0.48 10.2 ± 0.11
89.12 ± 0.62 7.76 ± 3.26 95.29 ± 0.82 2.66 ± 1.08
85.82 ± 0.01 3.82 ± 0.42 92.07 ± 1.41 3.98 ± 0.12
with specific antibodies to memory T cells (CD44, CD62L), and then analyzed
and methods.
CD62Lhi.


















































Figure 4 The protective activity against TB in young and middle-aged mice. BCG-vaccinated or unvaccinated mice, young (30-week old)
(a, b) or middle-aged (89-week old) (c, d), were intravenously challenged with 1 × 105 CFU of M. tuberculosis strain H37Rv. Middle-aged mice
(c, d) were non-boosted (open column), 3-times boosted by Oligo-B (solid column). Four weeks after challenge, the bacterial numbers in the
spleen (a, c) and lung (b, d) were determined by colony assay. Data represent mean ± SD from 8-10 mice. The results of Oligo-B-boosted mice
were obtained from 4 mice. ** p < 0.01, * p < 0.05, N.S.: not significant.
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cells (data not shown) and increased IFN-γ production
from splenocytes stimulated with OVA with increasing
age (Figure 2). Kim et al. reported that the non-specific
type immune responses increased with increasing age
[15]. The productions of tumor necrosis factor-α and IL-6
both in healthy individuals and patients suffering from age
related diseases increased with aging [16]. These studies
indicate that the age related immunological changes and
immune senescence in human are commonly observed in
mice, and duration of initial BCG vaccine would be
extinguished up to 57-week old.
Next, we investigated the reactivation of the protective
immunity against MTB infection in the immune senescent
mice by Oligo-B boosting (Figure 3). The CpG oligomer
was used as adjuvant conjugated with BCG [17] or MTB
antigens, such as Ag85B [18], MPT-51 [19], and MTB cul-
ture filtrate proteins [20]. The synthesized CpG oligomer,
Oligo-B, induced antigen presentation through toll-like re-
ceptor 9 (TLR-9) signaling in plasmacytoid dendritic cells
[21] and the production of Th17 cytokines [22], which is
known to play an important role in host defense against
MTB infection [23]. Therefore, these studies indicated that
CpG oligomer is a good inducer of IFN-γ and IL-17 and
reactivates acquired immunity. In fact, the production of
IFN-γ was reactivated by three times boosting of Oligo-B
in the super aged mice (Figure 3), therefore, Oligo-B couldgenerate the number of the memory T cell by IFN-γ and
IL-17.
Several studies reported that CD4+ memory T cells
were induced by BCG vaccination [24,25]. In our study
the number of TCM, CD44
hi, CD62Lhi, in CD4+ was
highly induced by the boosting with Oligo-B in the im-
mune senescent 81-90-old mice (Table 1, 2.85 ± 0.67 vs.
7.76 ± 3.26) and protection activity against MTB was re-
juvenated (Figure 4). These results suggest that Oligo-B
could induce TCM in CD4
+ which improved protection
activity against MTB infection.
In conclusion, this is the first report indicating that
Oligo-B boosting can rejuvenates the number of TCM in
CD4+ and reactivate the protection immunity against
MTB infection in the immune senescent state mice
formerly vaccinated with BCG. This report also provides
basic information to explore the prime-booster strategy
for preventing TB in adult.
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